Alogliptin (benzoate salt)

Alogliptin is an orally bioavailable dipeptidyl peptidase 4 (DPP-4) inhibitor (IC50 = 6.9 nM) that is selective for DPP-4 over DPP-2, DPP-8, DPP-9, prolyl endopeptidase, fibroblast activation protein (FAP), and tryptase (IC50s = >100,000 nM). It does not inhibit cytochrome P450 enzymes and does not block the human ether-a-go-go-related gene (hERG) channel when used at concentrations up to 30 µM. Alogliptin inhibits DPP-4 activity in vivo in rats, dogs, and cynomolgus monkeys (EC50s = 3.4, 4.9, and 5.6 ng/ml, respectively, in plasma). It increases plasma glucagon-like peptide-1 (GLP-1, Cay-24460) and insulin levels and decreases blood glucose levels during an oral glucose challenge in Zucker fa/fa rats when administered at a dose of 10 mg/kg. Alogliptin (2.8 mg/kg per day) decreases plasma DPP-4 activity and increases GLP-1 levels in diabetic ob/ob mice when administered for 29 days. Formulations containing alogliptin have been used as an adjunct treatment for type 2 diabetes mellitus.Formal Name: 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile, monobenzoate. CAS Number: 850649-62-6. Synonyms: SYR-322. Molecular Formula: C18H21N5O2 . C7H6O2. Formula Weight: 461.5. Purity: >98%. Formulation: (Request formulation change), A crystalline solid. Solubility: DMF: 0.1 mg/ml, DMSO: 0.1 mg/ml, Ethanol: slightly soluble, PBS (pH 7.2): 10 mg/ml. lambdamax: 225, 273 nm. SMILES: O=C(N(C)C1=O)C=C(N2C[C@H](N)CCC2)N1CC3=CC=CC=C3C#N.O=C(O)C4=CC=CC=C4. InChi Code: InChI=1S/C18H21N5O2.C7H6O2/c1-21-17(24)9-16(22-8-4-7-15(20)12-22)23(18(21)25)11-14-6-3-2-5-13(14)10-19,8-7(9)6-4-2-1-3-5-6/h2-3,5-6,9,15H,4,7-8,11-12,20H2,1H3,1-5H,(H,8,9)/t15-,/m1./s1. InChi Key: KEJICOXJTRHYAK-XFULWGLBSA-N.